Hubbry Logo
Blood plasma fractionationBlood plasma fractionationMain
Open search
Blood plasma fractionation
Community hub
Blood plasma fractionation
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Blood plasma fractionation
Blood plasma fractionation
Blood plasma fractionation
View on Wikipedia
from Wikipedia

Blood plasma fractionation are the general processes separating the various components of blood plasma, which in turn is a component of blood obtained through blood fractionation. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune inflammatory diseases.[citation needed]

Blood plasma

[edit]

Blood plasma is the liquid component of whole blood, and makes up approximately 55% of the total blood volume. It is composed primarily of water with small amounts of minerals, salts, ions, nutrients, and proteins in solution. In whole blood, red blood cells, leukocytes, and platelets are suspended within the plasma.[citation needed]

Plasma proteins

[edit]

Plasma contains a large variety of proteins including albumin, immunoglobulins, and clotting proteins such as fibrinogen.[1] Albumin constitutes about 60% of the total protein in plasma and is present at concentrations between 35 and 55 mg/mL.[2] It is the main contributor to osmotic pressure of the blood and it functions as a carrier molecule for molecules with low water solubility such as lipid-soluble hormones, enzymes, fatty acids, metal ions, and pharmaceutical compounds.[3] Albumin is structurally stable due to its seventeen disulfide bonds and unique in that it has the highest water solubility and the lowest isoelectric point (pI) of the plasma proteins. Due to the structural integrity of albumin it remains stable under conditions where most other proteins denature.[citation needed]

Plasma proteins for clinical use

[edit]

Many of the proteins in plasma have important therapeutic uses.[1] Albumin is commonly used to replenish and maintain blood volume after traumatic injury, during surgery, and during plasma exchange.[3] Since albumin is the most abundant protein in the plasma its use may be the most well known, but many other proteins, although present in low concentrations, can have important clinical uses.[1] See table below.[1]

Examples of Plasma Components for Clinical Use
Plasma Component Reasons for Use
factor VIII hemophilia A
factor IX hemophilia B
Factor X congenital deficiency
factor XIII congenital deficiency
PCC complex anticoagulant overdose

factor II and factor X if Factor X not available deficiencies liver disease

immunoglobulin passive prophylaxis

immune deficiency disorders
some types of immune thrombocytopenic purpura
Guillain–Barré syndrome
Polyneuropathies

antithrombin III congenital deficiency

disseminated intravascular coagulation

fibrinogen congenital deficiency

massive haemorrhage

C1 inhibitor hereditary angioedema
albumin hypoalbuminemia

Ascites Restoring of blood volume in trauma, burns and surgery patients

alpha-I-antitrypsin hereditary deficiencies

emphysema and COPD cirrhosis

Plasma processing

[edit]

When the ultimate goal of plasma processing is a purified plasma component for injection or transfusion, the plasma component must be highly pure. The first practical large-scale method of blood plasma fractionation was developed by Edwin J. Cohn during World War II. It is known as the Cohn process (or Cohn method). This process is also known as cold ethanol fractionation as it involves gradually increasing the concentration of ethanol in the solution at 5 °C and 3 °C.[3] The Cohn Process exploits differences in properties of the various plasma proteins, specifically, the high solubility and low pI of albumin. As the ethanol concentration is increased in stages from 0% to 40% the [pH] is lowered from neutral (pH ~ 7) to about 4.8, which is near the pI of albumin.[3] At each stage certain proteins are precipitated out of the solution and removed. The final precipitate is purified albumin. Several variations to this process exist, including an adapted method by Nitschmann and Kistler that uses fewer steps and replaces centrifugation and bulk freezing with filtration and diafiltration.[1][3]

Some newer methods of albumin purification add additional purification steps to the Cohn Process and its variations, while others incorporate chromatography, with some methods being purely chromatographic.[3] Chromatographic albumin processing as an alternative to the Cohn Process emerged in the early 1980s, however, it was not widely adopted until later due to the inadequate availability of large scale chromatography equipment.[3] Methods incorporating chromatography generally begin with cryodepleted plasma undergoing buffer exchange via either diafiltration or buffer exchange chromatography, to prepare the plasma for following ion exchange chromatography steps.[3] After ion exchange there are generally further chromatographic purification steps and buffer exchange.[3]

For further information see chromatography in blood processing.

Plasma for analytical uses

[edit]

In addition to the clinical uses of a variety of plasma proteins, plasma has many analytical uses. Plasma contains many biomarkers that can play a role in clinical diagnosis of diseases, and separation of plasma is a necessary step in the expansion of the human plasma proteome.[citation needed]

Plasma in clinical diagnosis

[edit]

Plasma contains an abundance of proteins many of which can be used as biomarkers, indicating the presence of certain diseases in an individual. Currently, 2D Electrophoresis is the primary method for discovery and detection of biomarkers in plasma. This involves the separation of plasma proteins on a gel by exploiting differences in their size and pI. Potential disease biomarkers may be present in plasma at very low concentrations, so, plasma samples must undergo preparation procedures for accurate results to be obtained using 2D Electrophoresis. These preparation procedures aim to remove contaminants that may interfere with detection of biomarkers, solubilize the proteins so they are able to undergo 2D Electrophoresis analysis, and prepare plasma with minimal loss of low concentration proteins, but optimal removal of high abundance proteins.[citation needed]

The future of laboratory diagnostics are headed toward lab-on-a-chip technology, which will bring the laboratory to the point-of-care. This involves integration of all of the steps in the analytical process, from the initial removal of plasma from whole blood to the final analytical result, on a small microfluidic device. This is advantageous because it reduces turn around time, allows for the control of variables by automation, and removes the labor-intensive and sample wasting steps in current diagnostic processes.[citation needed]

Expansion of the human plasma proteome

[edit]

The human plasma proteome may contain thousands of proteins, however, identifying them presents challenges due to the wide range of concentrations present. Some low abundance proteins may be present in picogram (pg/mL) quantities, while high abundance proteins can be present in milligram (mg/mL) quantities. Many efforts to expand the human plasma proteome overcome this difficulty by coupling some type of high performance liquid chromatography (HPLC) or reverse phase liquid chromatography (RPLC) with high efficiency cation exchange chromatography and subsequent tandem mass spectrometry for protein identification.[2][4]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Blood plasma fractionation

View on Grokipedia
from Grokipedia
Blood plasma fractionation is the industrial process of separating human blood plasma into its constituent proteins and other components to produce therapeutic medicines for clinical use. This separation typically involves a combination of physical and chemical techniques, such as cold ethanol precipitation, cryoprecipitation, , , and , to isolate high-purity fractions from large volumes of collected plasma. The resulting products are critical for treating a range of conditions, including bleeding disorders, immune deficiencies, and protein shortages, with global production exceeding 80 million liters of plasma annually as of 2024 estimates, primarily from source plasma. The origins of plasma fractionation trace back to the 1940s, when Edwin J. Cohn developed the foundational fractionation method during to produce and other proteins for military medical needs, enabling the scalable isolation of plasma components without denaturation. This cold process, refined over decades into the Cohn-Oncley and Kistler-Nitschmann (K-N) methods, relies on controlled adjustments in , , , and concentration to selectively precipitate proteins into fractions. By the , early explorations into chromatographic techniques emerged as alternatives to ethanol-based methods, with significant advancements in purification efficiency reported in 1977. Today, most plasma—about 80%—is sourced via from paid donors, while the remainder comes from recovered plasma as a byproduct of donations, all subjected to rigorous regulatory standards for quality and safety. The global market for plasma-derived products was valued at approximately USD 35-38 billion in 2024, projected to reach USD 70-80 billion by 2032-2034 due to rising demand for immunoglobulins and new indications. Key products derived from fractionation include for volume expansion and burn treatment, for primary immunodeficiencies and autoimmune diseases, coagulation factors like and for hemophilia, and protease inhibitors such as alpha-1-antitrypsin for genetic deficiencies. Over 25 distinct plasma proteins are now commercially available, addressing immunological, hematological, and metabolic disorders that affect millions worldwide, often as the sole therapeutic option where recombinant alternatives are unavailable or less effective. is paramount, with multi-step inactivation processes—including /detergent treatment, , and nanofiltration (using 15–50 nm filters for >10–12 log10 virus reduction)—ensuring viral security since the 1980s HIV crisis prompted stringent measures. In recent years, the industry has seen innovations like expanded bed adsorption achieving up to 67% yields for certain proteins and aqueous two-phase extraction reaching 92% IgG purity, alongside efforts toward continuous processing for higher efficiency. As of 2025, the global market continues to expand due to rising demand for IgG and new indications, with fractionation facilities—numbering over 80 worldwide—focusing on ethanol-free methods and enhanced recovery rates exceeding 90% for key products. Future trends emphasize novel technologies, such as with nanobodies, to meet growing needs amid challenges like emerging pathogens and supply constraints.

Fundamentals of Blood Plasma

Composition and Properties

is the straw-colored liquid component of , constituting approximately 55% of total and serving as the medium in which blood cells are suspended. It consists primarily of , accounting for 90% to 92% of its composition, with the remaining 8% to 9% comprising dissolved solids such as proteins, electrolytes, nutrients, hormones, and waste products. The protein content of plasma totals 60 to 80 g/L, with representing the predominant fraction at 35 to 50 g/L; these proteins collectively contribute to maintaining the plasma's colloidal , approximately 25 mmHg, which helps regulate between blood vessels and tissues. Non-protein components include electrolytes such as sodium (135–145 mmol/L), (3.5–5 mmol/L), and (98–107 mmol/L), which are essential for osmotic balance and pH regulation; glucose, typically 3.9–5.5 mmol/L in states; lipids like and triglycerides transported in forms; and dissolved gases including oxygen, , and . Key physical and chemical properties of plasma include a range of 7.35 to 7.45, which is slightly alkaline and tightly buffered by electrolytes and proteins to support enzymatic functions and oxygen . Its , approximately 1.2 to 1.3 mPa·s at 37°C, arises mainly from protein concentrations and influences flow resistance. Plasma plays a critical role in (e.g., glucose and ), waste removal (e.g., and ), and overall , making it the foundational material for processes that isolate therapeutic components.

Sources and Collection

Blood plasma for fractionation is primarily obtained from two sources: source plasma collected directly via plasmapheresis from healthy donors and recovered plasma derived from donations. In plasmapheresis, an automated process draws from the donor, separates the plasma using centrifugation within the apheresis machine, and returns the cellular components ( blood cells, , and platelets) along with saline to the donor, allowing for more frequent collections compared to donation. Recovered plasma, on the other hand, is separated from units collected for transfusion purposes, where the plasma is removed post-donation via centrifugation, leaving the blood cells for other uses. The vast majority of plasma used for manufacturing plasma-derived medicinal products comes from source plasma via plasmapheresis, as it enables higher volumes and repeated donations. Collection adheres to strict standards to ensure donor safety and plasma quality. In the United States, regulated by the (FDA), eligible donors must be at least 18 years old, weigh a minimum of 110 pounds (50 kg), and pass a comprehensive health screening, including medical history review and testing for infectious diseases such as , and C, and . Volume limits per session are determined by FDA-approved nomograms based on donor factors like sex, height, weight, and , with a typical maximum of up to 800 mL for qualifying adults. Frequency is capped at no more than twice per week, with at least 48 hours between donations, to minimize risks like protein depletion or dehydration. Post-collection processing begins immediately to preserve protein integrity. For recovered plasma from whole blood, centrifugation separates the plasma within hours of donation, followed by freezing at -20°C or lower within 24 hours to maintain clotting factors and other labile proteins. Source plasma from plasmapheresis is similarly frozen promptly after collection, often at -25°C to -30°C for optimal preservation, using rapid freezing methods to reach core temperatures below -25°C within 12 hours. Frozen plasma units are stored at -20°C or colder, with FDA guidelines permitting a shelf life of up to 10 years for source plasma intended for fractionation, though lower temperatures like -30°C can extend stability further. Globally, the plasma supply for relies heavily on a mix of paid and voluntary donations, with significant variations by region. The dominates as the largest supplier, providing approximately 70-75% of the world's source plasma through high-volume commercial centers that compensate donors, enabling frequent collections and meeting international demand for plasma-derived therapies. In contrast, many countries, including those in the , emphasize voluntary unpaid donations, which constitute over 90% of blood supplies in 79 nations but result in lower plasma volumes for due to less frequent collections. This reliance on U.S. paid plasma underscores the commercial nature of the global market, where the U.S. exports much of its supply to support worldwide.

Plasma Proteins

Types and Classification

Blood plasma contains a diverse array of proteins, with recent deep proteomic analyses identifying over 13,000 unique proteins as of , though plasma fractionation processes primarily target approximately 50 clinically relevant proteins that are structurally characterized and functionally significant. These proteins are classified by their primary functions, including carrier proteins such as , which binds and transports various molecules; immune proteins like immunoglobulins (IgG, IgA, and IgM), which contribute to ; clotting factors including fibrinogen and coagulation factors II, V, VIII, and IX, essential for ; and regulatory proteins such as components of the and enzymes like proteases, which modulate physiological processes. Plasma proteins are further categorized by their abundance, reflecting their relative concentrations in the protein-rich fluid component of blood. High-abundance proteins include , comprising 50-60% of total plasma proteins at concentrations of 35-50 g/L, and globulins, accounting for 35-45% or about 20-35 g/L. Medium-abundance proteins, such as fibrinogen, are present at 2-4 g/L, representing roughly 4-7% of the total. Low-abundance proteins, including many trace clotting factors and regulatory components, occur at concentrations below 1 mg/L, often in the range of 0.1-0.5 mg/L for specific factors like VIII. Structurally, most plasma proteins are glycoproteins, featuring moieties that influence their stability and interactions. Key examples include with a molecular weight of approximately 66 , enabling its high ; IgG at around 150 , composed of two heavy chains (50 each) and two light chains (22 each); and fibrinogen at about 340 as a dimeric . These proteins exhibit varying properties, such as differential precipitation in response to changes in , , and concentration, which underpin their separation during without compromising integrity.

Biological Functions

Plasma proteins serve essential physiological roles in maintaining , including osmotic balance, immune defense, and . These proteins, primarily synthesized by the liver, constitute about 7% of plasma's dry weight and include , globulins (such as immunoglobulins and clotting factors), and other regulatory components. Their functions are interconnected, ensuring fluid distribution, clearance, and clot formation to prevent excessive or . Albumin, the most abundant plasma protein at approximately 35-50 g/L, plays a critical role in maintaining , which is around 25 mmHg and counteracts hydrostatic pressure to retain fluid within the vascular compartment. This prevents by regulating the movement of across walls. Additionally, acts as a carrier for various substances, binding and transporting fatty acids, , hormones, and drugs throughout the bloodstream, thereby facilitating their distribution and metabolism. Immunoglobulins, or antibodies, are key components of adaptive immunity, produced by plasma cells in response to antigens. They mediate antibody-dependent immunity through mechanisms such as opsonization, where they coat to enhance by immune cells like macrophages, and neutralization, which blocks pathogen attachment to host cells by binding to viral or bacterial surface proteins. These actions protect against infections from , viruses, fungi, and parasites, with major classes including IgG (opsonization and complement activation) and IgM (early response and ). Clotting factors, a group of plasma proteins such as fibrinogen, prothrombin, and factors VIII and IX, orchestrate the coagulation cascade to achieve . This enzymatic cascade amplifies signals to form a stable clot: cleaves fibrinogen into insoluble strands that polymerize into a mesh, trapping platelets and red blood cells to seal vascular injuries. , in complex with , accelerates activation in the intrinsic pathway, crucial for amplifying the response; its deficiency underlies hemophilia A, leading to impaired clot formation and prolonged bleeding. The , comprising over 30 plasma proteins including C3 and C5, contributes to innate immunity by opsonizing pathogens, promoting through anaphylatoxins like C5a that recruit immune cells, and lysing microbes via the membrane attack complex. Complement enzymes, activated in classical, alternative, or pathways, also modulate by cleaving proteins to generate chemotactic signals and enhance efficacy. Other plasma enzymes, such as those in the fibrinolytic system (e.g., derived from plasminogen), facilitate protein degradation by breaking down clots post-hemostasis, preventing while regulating inflammatory responses. Deficiencies in plasma proteins disrupt these interdependent functions, often leading to disease. For instance, reduces , causing fluid leakage into tissues and resulting in or , as seen in liver where impaired synthesis exacerbates . Immunoglobulin deficiencies impair pathogen neutralization, increasing infection susceptibility, while clotting factor shortages like deficiency provoke hemorrhagic disorders. Complement deficiencies heighten autoimmune or infectious risks due to unchecked or poor clearance.

History of Plasma Fractionation

Early Developments

The foundations of blood plasma fractionation emerged in the 19th century through initial explorations of blood protein separation. In 1856, French chemist Paul-Sébastien Denis demonstrated the separation of blood proteins into albumins and globulins using salt precipitation, providing an early method to exploit differences in protein for isolation from serum. During the 1860s, German physiological chemist Felix Hoppe-Seyler advanced the understanding of plasma components through detailed analyses of blood, including the isolation and characterization of several proteins (termed "proteids" at the time), which highlighted the diversity of soluble fractions in plasma. In the early , plasma gained recognition as a viable , particularly amid the demands of , where transfusions were logistically challenging. Researchers explored plasma's volume-expanding properties to treat hemorrhagic shock, leading to the 1918 introduction of dried plasma for battlefield transfusions, which offered greater stability and ease of transport compared to liquid . Edwin J. Cohn's research at in the 1920s and 1930s built on these foundations by investigating protein curves, employing to fractionate serum proteins and elucidate their physicochemical behaviors under varying salt concentrations. This work addressed persistent challenges in plasma preparation, including coagulation prevention via anticoagulants like and bacterial contamination through aseptic collection, refrigeration, and early sterilization protocols. By 1939, the establishment of the first organized plasma banks facilitated systematic storage and distribution, marking a pivotal shift toward scalable clinical application.

World War II and Cohn Process

During , the urgent need for stable blood products to treat shock, burns, and hemorrhage in combat zones drove rapid advancements in plasma fractionation, as the anticipated involvement in the conflict by spring 1940. The U.S. Navy, through the National Research Council, sponsored research led by Edwin J. Cohn at from 1940 to 1945, aiming to develop concentrated human as a plasma substitute that could be easily transported and administered in small volumes without the risks associated with transfusions, such as incompatibility. This wartime effort transformed Cohn's pre-war studies on protein chemistry into a practical industrial process, enabling the production of fractionated plasma components for military use. The Cohn process, a cold method, was developed in 1940 and ed in 1945 (filed as a continuation from 1940), involving stepwise of plasma proteins through controlled adjustments of concentration (8-40%), (0-5°C), pH (4.8-7.2), ionic , and protein concentration. This technique separated plasma into five major fractions: Fraction I (rich in fibrinogen), Fractions II and III (containing gamma globulins and other globulins), Fraction IV (alpha and beta globulins), and Fraction V (primarily ). Key collaborators included John T. Edsall, who contributed to the biochemical understanding and large-scale procedures for protein separation. The method exploited differences in protein to isolate pure components efficiently, with from Fraction V serving as the primary product for volume expansion . Production scaled up dramatically through a Harvard pilot plant and contracts with seven commercial firms, processing over 2.3 million blood donations and yielding more than 570,000 packages of albumin by the war's end in 1945, alongside other fractions totaling over 1.2 million units. The first commercial human albumin solution (25% concentration) was authorized for production in January 1942 and became available for clinical use by 1944, following successful trials starting in April 1941. This enabled mass distribution to troops, as demonstrated at Pearl Harbor in December 1941, where albumin helped save burn casualties who might otherwise have perished from shock. The Cohn process significantly reduced transfusion risks by providing stable, heat-sterilizable products that avoided whole blood's logistical challenges and serological incompatibilities, while facilitating the isolation of therapeutic proteins for broader medical applications. Its success marked a pivotal shift toward industrialized production, saving countless lives during the war and establishing as a cornerstone of modern plasma .

Fractionation Techniques

Cold Ethanol Fractionation

Cold ethanol fractionation is a cornerstone method for initial separation of proteins, relying on the differential solubility of proteins in solutions at low temperatures. Developed by J. Cohn and colleagues during , this technique precipitates proteins sequentially by adjusting concentration, pH, ionic strength, and temperature to target their isoelectric points and minimize denaturation. It remains widely used in the early stages of industrial plasma processing due to its scalability and effectiveness in isolating major protein classes like fibrinogen, immunoglobulins, and . The procedure starts with thawing frozen plasma at 1–5°C to remove , yielding cryo-poor plasma that undergoes sequential additions. Proteins are precipitated by gradual increases in , with each fraction isolated via or ; the supernatant proceeds to the next step. The classic Cohn method 6 divides plasma into five main fractions: I (fibrinogen-rich), II+III (immunoglobulins and clotting factors), sub-fractions of III and IV (globulins), and V (). Specific conditions for each precipitation are tightly controlled, as summarized below:
FractionEthanol (%)pHTemperature (°C)Key Proteins PrecipitatedProtein Yield (% of total)
I8–106.9–7.2–3 to –5Fibrinogen, , 5–10
II+III20–256.8–7.0–5IgG, IgA, IgM, clotting factors II, VII, IX, X25
III18–205.2–5.4–5Additional globulinsNot specified
IV-118–255.2–6.1–5α- and β-globulins, IgM, III5–10
IV-420–404.8–6.1–5α- and β-globulins, , 5–10
V404.8–5.1–5 (85–98% purity)60–70
These parameters exploit protein charge and hydrophobicity differences, with typically maintained low (e.g., 0.06–0.3 M) using or citrate buffers. Large-scale implementation requires refrigerated continuous-flow centrifuges (e.g., disc-stack models operating at 4,000–6,000 rpm) for precipitate separation, depth filters (e.g., beds) for clarification, and jacketed mixing tanks with cooling coils to sustain sub-zero temperatures. Yields vary by fraction but achieve overall protein recovery of 90–95%, with at 60–70% and immunoglobulins at around 50% from starting plasma (typically 50–60 g/L total protein). Advantages of cold ethanol fractionation include high scalability for processing thousands of liters daily, cost-effectiveness using inexpensive as both precipitant and agent, and robust partitioning of enveloped viruses during steps. However, limitations encompass co- of impurities necessitating downstream purification, potential protein denaturation from ethanol exposure, suboptimal yields for minor proteins (e.g., <10% for some clotting factors), and challenges in removing non-enveloped viruses without additional treatments.

Modern Chromatographic Methods

Modern chromatographic methods represent a significant advancement in blood plasma fractionation, offering precise separation capabilities that surpass the limitations of traditional precipitation techniques by enabling higher purity and recovery of target proteins. These methods, typically integrated after initial bulk separation steps, leverage differences in protein charge, affinity, size, and hydrophobicity to isolate therapeutic components with minimal denaturation and improved scalability. Widely adopted since the late 20th century, they have become essential for producing high-value plasma derivatives, addressing the dynamic range challenges of low-abundance factors like coagulation proteins. Ion-exchange chromatography separates proteins based on their net surface charge interactions with charged resins, utilizing anion exchangers like DEAE-Sepharose for albumin purification, which routinely achieves purities exceeding 99%. Cation and anion exchangers are also employed for globulin isolation and coagulation factor enrichment, such as in prothrombin complex or factor IX concentrates, with process yields reaching up to 70% for these proteins. This technique's selectivity at physiological pH minimizes protein aggregation and supports downstream viral clearance. Affinity chromatography provides ligand-specific binding for targeted purification, with Protein A resins binding the Fc region of immunoglobulin G (IgG) to enable high-specificity isolation and recoveries over 95%, often as a polishing step for intravenous immunoglobulin products. Heparin-affinity columns exploit interactions with glycosaminoglycan-binding sites on coagulation factors like antithrombin and factor IX, yielding functional proteins at purities above 98% while preserving enzymatic activity. These methods excel in removing host cell impurities and isoforms, enhancing product homogeneity. Size-exclusion chromatography, or gel filtration, sorts proteins by hydrodynamic volume using porous matrices, facilitating the separation of alpha-1-antitrypsin and factor VIII based on molecular weight differences to achieve baseline resolution and yields up to 70%. Hydrophobic interaction chromatography (HIC) complements this by eluting proteins according to surface hydrophobicity under high-salt conditions, commonly applied to aggregate removal or final polishing of globulins, contributing to overall process purities greater than 99%. Both techniques are valued for their orthogonality to other methods, reducing non-specific binding. Hybrid processes combining these chromatographic techniques with initial ethanol fractionation have optimized industrial workflows, for instance, boosting IgG yields to 3.5-4.5 g/L plasma through sequential anion-exchange and affinity steps. Automation via perfusion systems enhances throughput by continuous loading, while post-2020 innovations like novel affinity ligands (e.g., nanobodies and CaptureSelect) and expanded bed adsorption have improved low-abundance protein recovery, with IgG processes achieving 67% yields and addressing scalability in single-use formats. These integrations tackle purity challenges in complex mixtures, routinely delivering >99% pure products at 70% recovery for key fractions.

Therapeutic Products

Albumin and Volume Expanders

(HSA), the most abundant protein in , is a key therapeutic product derived from plasma fractionation, primarily serving as a in medical applications. It is typically produced as sterile aqueous solutions in concentrations of 5% or 25%, with the 5% formulation providing isotonic replacement and the 25% offering hypertonic expansion for more concentrated dosing. These solutions are manufactured through cold ethanol fractionation of human plasma, where HSA is isolated from Fraction V, followed by purification steps including and to achieve high purity levels exceeding 96%. To ensure viral safety, the final product undergoes terminal heat at 60°C for 10 hours, a process that inactivates enveloped viruses while preserving the protein's structural integrity. The primary mechanism of fractionated HSA involves its oncotic properties, which draw fluid into the intravascular space to restore circulating volume, particularly in states of , burns, or surgical blood loss. As a 66.5 monomeric protein, HSA maintains colloidal and binds to various ligands, contributing to hemodynamic stability. Its in circulation is approximately 20 days, allowing for sustained effects following administration. In the Cohn cold fractionation process, albumin yields typically range from 20-30 g per liter of starting plasma, highlighting its efficient recovery as a major plasma component. Global demand for plasma-derived HSA is approximately 1,000 tons annually as of 2023, sourced from large pools of screened human plasma to support critical care needs worldwide. The product is often supplied in lyophilized form for enhanced stability, remaining viable for years when stored desiccated at controlled temperatures, with reconstitution yielding a clear, viscous solution suitable for intravenous use. While synthetic and recombinant alternatives, such as - or yeast-derived HSA, have emerged to address supply limitations, fractionated HSA remains the clinical standard due to its native and established safety profile from decades of use.

Coagulation Factors and Immunoglobulins

Blood plasma fractionation yields several critical coagulation factors essential for , primarily through processes like and chromatographic purification. , also known as anti-hemophilic factor, is predominantly isolated from the fraction obtained after thawing frozen plasma at 1–6°C, where it precipitates along with fibrinogen, , and . This initial step achieves yields of approximately 200 IU of per kg of starting plasma in intermediate-purity concentrates, followed by further purification using to enhance and remove impurities. , used in the treatment of hemophilia B, is extracted from the cryo-poor plasma supernatant via adsorption onto ion-exchange resins or direct chromatographic capture, often as part of a prothrombin complex that includes Factors II, VII, IX, and X. These complexes are purified using a combination of ethanol fractionation and modern or cation-exchange to achieve high potency while minimizing viral contaminants. Immunoglobulins represent another major class of therapeutic proteins derived from plasma fractionation, with intravenous immunoglobulin (IVIG) being a pooled preparation of primarily IgG antibodies sourced from thousands of donors to provide broad-spectrum for primary immunodeficiencies. IVIG is produced by sequential cold (Cohn Fractions II and III) followed by chromatographic steps, such as ion-exchange and hydrophobic interaction , to isolate and purify IgG with minimal IgA and IgM content. Hyperimmune variants, like anti-RhD immunoglobulin, are similarly fractionated from plasma donated by deliberately immunized Rh-negative individuals, concentrating specific antibodies against the RhD to prevent . Standard dosing for IVIG in replacement therapy ranges from 0.4 to 1 g/kg body weight, administered intravenously every 3–4 weeks to maintain trough levels above 4–6 g/L. Both factors and immunoglobulins are formulated as lyophilized powders for reconstitution or as stabilized liquid solutions containing stabilizers like or to prevent aggregation and maintain bioactivity during storage. These products typically have a of 2–3 years when refrigerated at 2–8°C, with some IVIG preparations stable for up to 36 months from manufacture, though they must not be frozen to preserve structural integrity. Post-thaw or reconstitution stability is limited to 24–48 hours at to ensure efficacy and safety.

Leading Manufacturers

The leading manufacturers of plasma-derived therapies include CSL Behring, Grifols, Takeda, and Octapharma. These companies produce a range of products such as intravenous immunoglobulin (IVIG), albumin, and coagulation factors, for example, Kcentra, a prothrombin complex concentrate from CSL Behring.

Clinical Applications

Indications for Use

Blood plasma fractionation produces therapeutic proteins used to address specific deficiencies and pathophysiological states. These products, including , immunoglobulins, and factors, are indicated for conditions where their targeted replacement restores critical functions such as , immune defense, or . , derived from plasma, is indicated as a second-line for with or without shock when adequate crystalloid fails to maintain hemodynamic stability. In severe burns exceeding 30% of total , is administered after the first 24 hours of to minimize fluid overload while preserving intravascular volume and reducing . For ascites in patients with , particularly following large-volume (>5 L fluid removal), prevents post-procedural circulatory dysfunction and renal impairment. During procedures, is used to prime the extracorporeal circuit and support volume expansion in cases of intraoperative . Subgroup analyses of randomized controlled trials, such as the ALBIOS study, indicate that supplementation may reduce 90-day mortality by approximately 6% in patients with compared to crystalloids alone. Intravenous immunoglobulins (IVIG), fractionated from pooled plasma, are indicated for primary immunodeficiencies including , where they provide essential antibody replacement to prevent recurrent bacterial infections and associated complications like chronic lung disease. In Kawasaki disease, high-dose IVIG is used to mitigate and reduce the incidence of coronary artery aneurysms. For Guillain-Barré syndrome, IVIG accelerates neurological recovery, shortens hospital stays, and offers efficacy comparable to plasma exchange in moderate to severe cases. Coagulation factor concentrates from plasma fractionation are essential for managing inherited and acquired bleeding disorders. concentrates are indicated for the prevention and treatment of bleeding episodes in hemophilia A, targeting factor VIII levels of 40-100% depending on bleed severity (e.g., hemorrhage or intracranial events). concentrates serve a similar role in hemophilia B, with dosing adjusted to achieve 40-100% activity for analogous bleeding scenarios. In , particularly types unresponsive to (e.g., types 2B, 3), plasma-derived concentrates containing alongside are used to control mucosal and surgical bleeding. Prothrombin complex concentrates (PCC) are indicated for urgent reversal of warfarin-induced anticoagulation in patients with acute major bleeding, such as , or requiring immediate invasive procedures, with dosing based on pre-treatment INR (e.g., 25-50 units/kg). The includes these plasma-derived products on its Model List of , endorsing their use for , burns, immune deficiencies, , Guillain-Barré syndrome, hemophilia, , and vitamin K antagonist reversal based on established clinical evidence.

Administration and Efficacy

Plasma-derived products from fractionation, such as , intravenous immunoglobulin (IVIG), and coagulation factors like , are primarily administered via intravenous to ensure rapid systemic distribution and therapeutic effect. For solutions, the standard route is intravenous, with a typical rate of 1 to 2 mL per minute for a 5% concentration in the absence of shock, adjusted based on patient response to avoid fluid overload. In contrast, some immunoglobulin preparations, particularly for chronic replacement therapy, can be given subcutaneously (SCIG), allowing for self-administration at home with weekly or biweekly dosing into the fatty tissue of the or thighs, which provides more stable IgG levels compared to intermittent IVIG infusions. Dosing regimens vary by product and clinical need but are calculated to achieve target plasma levels. For prophylactic IVIG in , a common regimen is 400 to 600 mg/kg body weight administered every 3 to 4 weeks via intravenous infusion over several hours. For acute bleeding episodes in hemophilia A, concentrates are dosed at 50 IU/kg intravenously to raise factor levels to approximately 100% of normal, with repeat doses every 8 to 12 hours as needed until is achieved. dosing for volume expansion typically starts at 0.5 to 1 g/kg (equivalent to 10 to 20 mL/kg of 5% solution) infused over 30 to , titrated to hemodynamic response. Efficacy of these products is supported by clinical evidence demonstrating improved outcomes in specific scenarios. A meta-analysis of controlled trials in burn shock resuscitation found that albumin administration was associated with reduced mortality (pooled OR 0.34, 95% CI 0.19–0.58) compared to crystalloids alone, though the evidence is limited by small, old studies of poor quality. For IVIG, prophylactic use in immunodeficiency reduces infection rates by maintaining serum IgG trough levels above 500 mg/dL, with long-term studies showing decreased infection rates and associated complications, including reduced need for acute care, in treated patients. Factor VIII replacement effectively controls acute bleeds when dosed appropriately, preventing joint damage and improving quality of life in hemophilia. Adverse events are generally mild, with anaphylaxis occurring in less than 1% of IVIG infusions, primarily in patients with IgA deficiency, and managed by slowing the infusion rate. Post-infusion monitoring is essential to assess efficacy and safety, focusing on clinical and laboratory parameters. For coagulation products like , factor activity levels are checked 15 to 30 minutes post-infusion to confirm peak achievement, with follow-up assays at 24 hours to guide subsequent dosing; long-term monitoring in chronic therapy includes annual joint assessments for outcomes like prevention. Volume status after or plasma infusions is evaluated via , urine output, and if available, with laboratory checks for electrolytes and to detect overload or dilutional effects. In ongoing therapies, such as monthly IVIG, serum IgG levels are measured before infusions to ensure troughs remain therapeutic, correlating with reduced incidence over years of treatment.

Analytical and Diagnostic Uses

Biomarkers in Plasma

Blood plasma serves as a critical matrix for detecting biomarkers, which are measurable indicators of normal or pathological processes, primarily through the analysis of its protein components. These biomarkers enable early , monitoring, and of various diseases by reflecting changes in protein concentrations or patterns within the plasma proteome. Common plasma biomarkers include (CRP), which rises above 10 mg/L to indicate , often due to or tissue damage. Cardiac troponin, released upon myocardial injury, is a key marker for acute coronary syndromes and heart attacks. (PSA) serves as a for , with elevated levels prompting further investigation. Diagnostic techniques for plasma biomarkers primarily involve immunoassays, such as , which target specific proteins with high specificity for quantitative detection. is used to identify abnormal protein patterns, particularly in conditions like where monoclonal gammopathies appear as distinct bands. These biomarkers find applications in monitoring liver function via the albumin-to-globulin ratio, where imbalances signal chronic disease or . In renal disease, detected in urine, often accompanied by in plasma, indicates glomerular damage. For infectious diseases, acute phase reactants like CRP help track and response to therapy. Modern assays achieve detection limits down to the ng/mL range, enhancing sensitivity for low-abundance biomarkers, and are increasingly integrated into point-of-care testing for rapid clinical decisions.

Proteomics Research

Proteomics research in blood plasma fractionation has significantly advanced the mapping of the human plasma proteome, enabling deeper insights into protein diversity and function. The Human Plasma Proteome Project (HPPP), initiated by the Human Proteome Organization (HUPO) in the early 2000s, represented a landmark effort to catalog plasma proteins systematically. Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), the project identified over 3,500 proteins with high confidence across multiple studies, highlighting the plasma proteome's vast complexity. This work underscored the proteome's dynamic range, spanning more than 10^{10}-fold from high-abundance proteins like albumin (approximately 35 mg/mL) to low-abundance cytokines such as interleukin-6 (around 5 pg/mL). Key techniques in plasma proteomics address the challenges of this by enhancing detection of lower-abundance species. Immunoaffinity depletion of the top six abundant proteins—such as , immunoglobulins, , , alpha-1-antitrypsin, and alpha-1-acid —removes up to 90% of total protein mass, improving sensitivity for subsequent analyses. Complementary methods include (2D-GE) for separating proteins by and molecular weight, followed by identification, and , which employs data-dependent LC-MS/MS to fragment and sequence peptides from complex digests. These approaches, often combined, have enabled comprehensive profiling while mitigating interference from dominant fractions. Post-2020 advancements have expanded proteome coverage beyond initial catalogs, with studies now routinely assessing over 10,000 plasma proteins through high-throughput platforms like Olink and SomaScan proximity extension assays. Artificial intelligence-assisted analysis, including machine learning for spectral annotation and pattern recognition, has further deepened these mappings by improving peptide identification accuracy and reducing false positives in large datasets. Such expansions have facilitated applications in biomarker discovery, particularly for cancer, where autoantibody panels—detecting tumor-specific autoantibodies in plasma—offer promising non-invasive screening tools, as demonstrated in early-stage lung cancer detection. Despite these progresses, proteomics research faces persistent challenges, including inter-sample variability due to physiological factors, collection protocols, and pre-analytical handling, which can confound . Detection of low-abundance proteins remains limited by the proteome's and instrument sensitivity, often requiring multiple enrichment steps to access rare species below ng/mL concentrations. Resources like the Plasma Proteome Database (PPD), developed under HUPO auspices, address these issues by compiling annotated data from thousands of experiments, providing a centralized repository for over 10,000 entries to support validation and cross-study comparisons.

Safety and Quality Control

Pathogen Inactivation Methods

Pathogen inactivation methods are essential steps in blood plasma fractionation to eliminate or reduce the risk of transmitting viruses, , and other contaminants from donor plasma to therapeutic products. These techniques are integrated into the process after initial fractionation steps, targeting both enveloped viruses (such as , HBV, and HCV) and non-enveloped viruses (such as HAV and ). The primary approaches include physical and chemical treatments that disrupt viral structures or remove pathogens through , ensuring the safety of plasma-derived products like , factors, and immunoglobulins. Physical methods, particularly , have been foundational since the mid-20th century. Pasteurization involves heating the product in at 60°C for 10 hours, often with stabilizers like sugars or to protect proteins; this achieves at least 6.4 for and 4.2 log for HAV. Dry heat treatment, applied to lyophilized products, uses higher temperatures such as 80°C for 72 hours or 100°C for 30 minutes, effectively inactivating enveloped viruses and some non-enveloped ones, though it is less effective against parvovirus B19. These heat-based methods are commonly used for and coagulation factors, respectively. Solvent-detergent (S/D) treatment is a chemical-physical process targeting lipid-enveloped viruses by disrupting their membranes. It typically employs 0.3% tri(n-butyl) (TNBP) combined with 1% Tween 80 or at 24–37°C for 4–6 hours, yielding over 11 log reduction for and similar efficacy against HBV and HCV. This method is widely applied to intermediate plasma pools or final products like immunoglobulins and , with residual agents removed via or oil extraction afterward. However, S/D is ineffective against non-enveloped viruses, necessitating complementary techniques. Emerging methods address limitations of traditional approaches by incorporating photochemical and filtration technologies. Methylene blue photoinactivation, combined with visible or UV light, targets enveloped viruses in fresh-frozen plasma, achieving significant reductions while minimizing protein damage; it has been adapted for fractionated products. Amotosalen/UVA treatment, a psoralen-based system originally for platelets, inactivates both enveloped and some non-enveloped viruses in plasma components through DNA/RNA cross-linking. Nanofiltration uses virus-retentive filters with 15–35 nm pores to physically remove pathogens by size exclusion, providing at least 6.8 log reduction for HAV and 6.6 log for bovine viral diarrhea virus (a model for HCV); it is particularly effective against non-enveloped viruses and is integrated into production of coagulation factors and immunoglobulins. Post-2020 advancements include visible light systems that further reduce protein denaturation compared to UV-based methods. As of 2025, visible light systems using 405 nm wavelengths have demonstrated effective inactivation of SARS-CoV-2 in plasma, offering reduced protein denaturation compared to UV methods. Overall efficacy of these methods exceeds 4 log reduction for major enveloped viruses like and HBV across combined processes, contributing to no reported transmissions of , HCV, or HBV via plasma derivatives since the 1990s. Limitations include potential inactivation or reduced activity of heat-labile coagulation factors, such as Factor V, with losses of 10–30% in activity during heat treatments. Nanofiltration may decrease product yields due to retention of large proteins, while photochemical methods can introduce minor toxicities or require additional validation for emerging pathogens like . These challenges underscore the need for multi-step inactivation strategies tailored to specific products.

Regulatory Standards and Oversight

Blood plasma fractionation is subject to stringent regulatory oversight by major international agencies to ensure the safety, quality, and efficacy of plasma-derived medicinal products (PDMPs). In the United States, the (FDA) regulates plasma fractionation under current good manufacturing practices (cGMP) for biologics, as outlined in 21 CFR Parts 210, 211, and 600-680, which mandate compliance for manufacturing facilities handling source plasma and finished products. In the , the (EMA) oversees the process through the Plasma Master File (PMF) certification, a centralized system requiring detailed documentation on plasma collection, testing, and processing to verify compliance with EU directives on quality and safety. The (WHO) provides voluntary standards for essential PDMPs, such as immunoglobulins and coagulation factors, emphasizing self-sufficiency in plasma supply and adherence to good manufacturing practices (GMP) for blood establishments to support access in low- and middle-income countries. Core standards focus on donor screening, product testing, and supply chain integrity. Donor testing includes mandatory nucleic acid testing (NAT) for HIV-1 and hepatitis C virus (HCV), implemented universally since 1999 to detect infections during the window period before seroconversion, reducing transfusion-transmissible risks by up to 50-60 days for HCV and 11-15 days for HIV-1 compared to serological methods. Product release criteria require potency assays to confirm therapeutic activity—such as functional tests for clotting factors—and sterility testing to ensure absence of microbial contamination, with specifications aligned to pharmacopoeial standards like those in the European Pharmacopoeia. Traceability is enforced from donor identification through processing to patient administration, enabling rapid recall if needed, as stipulated in EU Directive 2003/63/EC and FDA requirements under 21 CFR 606. Global variations reflect differing ethical and epidemiological priorities. In the , while donations must be voluntary and non-remunerated per Directive 2002/98/EC to prioritize , plasma apheresis donations may include reimbursement for time and inconvenience, facilitating higher collection volumes for without compromising safety standards. Post-2020 updates have addressed variant Creutzfeldt-Jakob disease (vCJD) risks, with the Commission on Human Medicines endorsing in 2020 for immunoglobulins and extending in 2022 to that UK-sourced plasma poses negligible vCJD transmission risk for manufacturing due to enhanced donor deferral and processing safeguards, reflected in the FDA's 2022 guidance, which relaxed donor deferral recommendations and permitted the use of UK-sourced plasma for manufacturing due to the negligible vCJD transmission risk. Oversight includes routine audits, adverse event monitoring, and international harmonization efforts. Pharmacovigilance systems track incidents like transfusion-related acute lung injury (TRALI), a leading cause of transfusion fatalities linked to anti-HLA antibodies in plasma products, requiring hemovigilance reporting to agencies like the FDA's MedWatch or EMA's EudraVigilance for risk mitigation through donor screening. Recalls are triggered by deviations in GMP, such as , with FDA's biologics deviation reporting under 21 CFR 600.14 ensuring swift action. occurs via International Council for Harmonisation (ICH) guidelines, such as Q5C for stability testing and Q6B for biotechnological product specifications, adapted for PDMPs to align quality controls across regions, including integration of pathogen inactivation as a standard compliance element.

References

  1. https://aob.amegroups.org/article/view/4496/html
  2. https://www.strategicmarketresearch.com/market-report/plasma-fractionation-market
  3. https://ipfa.nl/the-past-present-and-future-of-blood-plasma-fractionation/
  4. https://aob.amegroups.org/article/view/11497/html
  5. https://www.grandviewresearch.com/industry-analysis/plasma-fractionation-market-report
  6. https://marketingresearchbureau.com/the-global-plasma-fractionation-landscape-through-2032/
  7. https://www.hematology.org/education/patients/blood-basics
  8. https://www.ncbi.nlm.nih.gov/books/NBK531504/
  9. https://www.news-medical.net/health/Blood-Plasma-Components-and-Function.aspx
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2821640/
  11. https://www.ncbi.nlm.nih.gov/books/NBK526080/
  12. https://www.ncbi.nlm.nih.gov/books/NBK541081/
  13. https://medlineplus.gov/lab-tests/chloride-blood-test/
  14. https://www.ncbi.nlm.nih.gov/books/NBK507807/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6842957/
  16. https://www.pptaglobal.org/resources/plasma-collection-and-manufacturing
  17. https://www.grifols.com/en/-/plasmapheresis
  18. https://www.sciencedirect.com/science/article/pii/S0887796324000415
  19. https://www.cslplasma.com/blog/qualification-for-donating-plasma
  20. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/volume-limits-automated-collection-source-plasma
  21. https://www.cslplasma.com/faq
  22. https://www.redcrossblood.org/biomedical-services/blood-products-and-services/plasma.html
  23. https://aob.amegroups.org/article/view/4255/html
  24. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/section-3
  25. https://conversableeconomist.com/2018/06/12/blood-plasma-us-paid-donors-dominate-global-market/
  26. https://www.aabb.org/news-resources/news/article/2025/10/27/aabb2025--examining-the-future-of-volunteer-blood-donation
  27. https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability
  28. https://euobserver.com/health-and-society/ar31abb718
  29. https://www.nature.com/articles/s42004-025-01665-1
  30. https://clinical-laboratory-diagnostics.com/k18.html
  31. https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-proteins
  32. https://derangedphysiology.com/main/cicm-primary-exam/haematological-system/Chapter-016/constituents-and-functions-plasma
  33. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/plasma-protein
  34. https://www.ncbi.nlm.nih.gov/books/NBK459198/
  35. https://www.ncbi.nlm.nih.gov/books/NBK513460/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4159104/
  37. https://www.ncbi.nlm.nih.gov/books/NBK534215/
  38. https://www.ncbi.nlm.nih.gov/books/NBK482253/
  39. https://www.ncbi.nlm.nih.gov/books/NBK507850/
  40. https://www.ncbi.nlm.nih.gov/books/NBK545263/
  41. https://www.ncbi.nlm.nih.gov/books/NBK27100/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3097465/
  43. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/549122
  44. https://www.britannica.com/biography/Ernst-Felix-Immanuel-Hoppe-Seyler
  45. https://achh.army.mil/history/book-wwii-blood-chapter11/
  46. https://profiles.nlm.nih.gov/spotlight/bg/feature/blood
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC10331509/
  48. https://www.sciencedirect.com/science/article/pii/S1045105625000405
  49. https://patents.google.com/patent/US2390074A/en
  50. https://www.genengnews.com/insights/in-line-process-analytics-for-fractionation/
  51. https://learncheme.com/wp-content/uploads/Prausnitz/Health/BloodTransfusionsCohnProcess.pdf
  52. https://press.asimov.com/articles/cohn
  53. https://www.infectedbloodinquiry.org.uk/reports/fractionation-report.html
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC7125842/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC5434990/
  56. https://onlinelibrary.wiley.com/doi/10.1111/voxs.12269
  57. https://www.fda.gov/media/70413/download
  58. https://labeling.cslbehring.com/pi/us/albuminar5/en/albuminar5-prescribing-information.pdf
  59. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-640/subpart-H
  60. https://link.springer.com/article/10.1007/s40138-023-00268-1
  61. https://journals.lww.com/hep/fulltext/2025/01000/controversies_regarding_albumin_therapy_in.26.aspx
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC5241407/
  63. https://www.sciencedirect.com/science/article/pii/S0889157525011986
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC3223471/
  65. https://www.statista.com/statistics/756572/albumin-worldwide-sales/
  66. https://link.springer.com/article/10.1208/s12248-024-00900-2
  67. https://www.atlantisbioscience.com/blog/recombinant-human-serum-albumin-vs-plasma-derived-human-serum-albumin/
  68. https://pubmed.ncbi.nlm.nih.gov/3103269/
  69. https://www.researchgate.net/publication/26722106_Intravenous_immunoglobulin_G_Trends_in_production_methods_quality_control_and_quality_assurance
  70. https://onlinelibrary.wiley.com/doi/10.1111/j.1423-0410.2009.01226.x
  71. https://professionaleducation.blood.ca/en/transfusion/clinical-guide/immunoglobulin-products
  72. https://www.cvsspecialty.com/content/dam/enterprise/specialty/images/resource_center/pdfs/ig_drug_comparison.pdf
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC2997296/
  74. https://www.linkedin.com/pulse/top-plasma-therapeutics-companies-how-compare-them-2026-o1xxf/
  75. https://www.globenewswire.com/news-release/2025/04/16/3062459/0/en/U-S-Plasma-Derived-Therapies-Market-Research-2025-2035-Competitive-Analysis-of-BIOLIFE-CSL-Behring-Grifols-Octapharma-Kedrion-LFB-Group-Emergent-BioSolutions-and-RAAS-Blood-Product.html
  76. https://www.verifiedmarketresearch.com/blog/top-blood-plasma-derivatives-companies/
  77. https://www.ncbi.nlm.nih.gov/books/NBK534241/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC2719274/
  79. https://www.ccjm.org/content/91/7/405
  80. https://www.ncbi.nlm.nih.gov/books/NBK554446/
  81. https://www1.wfh.org/publication/files/pdf-1137.pdf
  82. https://www.ncbi.nlm.nih.gov/books/NBK539716/
  83. https://aob.amegroups.org/article/view/4205/html
  84. https://www.fda.gov/media/70406/download
  85. https://www.drugs.com/dosage/albumin-human.html
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC2801034/
  87. https://www.ncbi.nlm.nih.gov/books/NBK551607/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC4851230/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC1809480/
  90. https://emedicine.medscape.com/article/779322-treatment
  91. https://www.jacionline.org/article/S0091-6749%2808%2901561-3/fulltext
  92. https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novoeight/dosing-administration.html
  93. https://www.ncbi.nlm.nih.gov/books/NBK499929/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC8169444/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC7122703/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC1277047/
  97. https://www.science.gov/topicpages/s/serum%2Bpsa%2Bconcentration
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC9421952/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC10967543/
  100. https://www.testing.com/tests/total-protein-albumin-globulin-ag-ratio/
  101. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-866/subpart-F
  102. https://stacks.cdc.gov/view/cdc/186399/cdc_186399_DS1.pdf
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC11965387/
  104. https://peptideatlas.org/hupo/hppp/
  105. https://pubs.acs.org/doi/10.1021/acs.jproteome.9b00503
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC5615924/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC2948641/
  108. https://www.researchgate.net/publication/7692447_Application_of_2-D_free-flow_electrophoresisRP-HPLC_for_proteomic_analysis_of_human_plasma_depleted_of_multi_high-abundance_proteins
  109. https://www.mcponline.org/article/S1535-9476%2820%2935062-3/pdf
  110. https://www.researchgate.net/publication/385804680_Proteome-wide_assessment_of_10000_plasma_proteins_with_age-related_diseases_and_multi-morbidity_in_a_Chinese_population
  111. https://www.nature.com/articles/s41467-025-57430-4
  112. https://www.mcponline.org/article/S1535-9476%2820%2930576-4/fulltext
  113. https://www.embopress.org/doi/10.15252/emmm.201910427
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC2494793/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC3965042/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC7169823/
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC9967166/
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC7169281/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC8552801/
  120. https://www.fda.gov/media/73834/download
  121. https://www.ema.europa.eu/en/human-regulatory-overview/plasma-master-file-pmf-certification
  122. https://www.who.int/publications/i/item/9789240021815
  123. https://www.nejm.org/doi/full/10.1056/NEJMoa040085
  124. https://www.fda.gov/media/124144/download
  125. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf
  126. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606
  127. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:31998H0463
  128. https://www.gov.uk/government/publications/use-of-uk-plasma-for-the-manufacture-of-albumins-and-vcjd-risk/use-of-uk-plasma-for-the-manufacture-of-albumins-and-vcjd-risk
  129. https://www.fda.gov/media/124156/download
  130. https://professionaleducation.blood.ca/en/transfusion/publications/transfusion-related-acute-lung-injury-trali
  131. https://www.fda.gov/media/70694/download
  132. https://database.ich.org/sites/default/files/Q5C_Guideline.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.